Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13061573 | 0.98 | LMNA (0.46) | LMNACYP3A4OPRM1ALDH1A1CA12 | |
| SCHEMBL13972410 | 0.95 | LMNA (0.46) | LMNACYP3A4OPRM1ALDH1A1L3MBTL1 | |
| SCHEMBL19035589 | 0.93 | LMNA (0.50) | LMNACYP3A4OPRM1ALDH1A1L3MBTL1 | |
| SCHEMBL28169231 | 0.93 | LMNA (0.50) | LMNACYP3A4OPRM1ALDH1A1L3MBTL1 | |
| SCHEMBL13909185 | 0.93 | LMNA (0.50) | LMNACYP3A4OPRM1ALDH1A1L3MBTL1 | |
| SCHEMBL20253209 | 0.93 | LMNA (0.50) | LMNACYP3A4OPRM1ALDH1A1L3MBTL1 | |
| SCHEMBL3987510 | 0.91 | LMNA (0.48) | LMNACYP3A4OPRM1ALDH1A1L3MBTL1 | |
| SCHEMBL13972408 | 0.91 | LMNA (0.48) | LMNACYP3A4OPRM1ALDH1A1CA2 | |
| SCHEMBL101110 | 0.91 | LMNA (0.46) | LMNACYP3A4OPRM1ALDH1A1CA12 | |
| SCHEMBL20253213 | 0.88 | LMNA (0.50) | LMNACYP3A4OPRM1ALDH1A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023161295-A1 | CLEANING CONCENTRATE FOR TURBINE JET ENGINES, CLEANING SOLUTION AND USE THEREOF | Alfred Kärcher SE & Co. KG (DE) | 2023-08-31 | — | — | WO | claimed |
| WO-2023161295-A1 | CLEANING CONCENTRATE FOR TURBINE JET ENGINES, CLEANING SOLUTION AND USE THEREOF | Alfred Kärcher SE & Co. KG (DE) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023161295-A1 | CLEANING CONCENTRATE FOR TURBINE JET ENGINES, CLEANING SOLUTION AND USE THEREOF | Alfred Kärcher SE & Co. KG (DE) | 2023-08-31 | — | — | WO | disclosed |
| EP-2473484-B1 | ORGANOPHOSPHORUS COMPOUNDS BASED ON TETRAPHENOL (TP)-SUBSTITUTED STRUCTURES | EVONIK DEGUSSA GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| EP-2886533-A1 | Use of Organophosphorus compounds based on tetraphenol (TP)-substituted structures | Evonik Degussa GmbH (DE) | 2015-06-24 | — | — | EP | disclosed |
| US-8940943-B2 | Cosmetic preparations | COGNIS IP MANAGEMENT GMBH (DE) | 2015-01-27 | — | — | US | disclosed |
| US-8940943-B2 | Cosmetic preparations | COGNIS IP MANAGEMENT GMBH (DE) | 2015-01-27 | — | — | US | disclosed |
| EP-2132167-B1 | METHOD FOR THE PRODUCTION OF beta-KETONITRILES | BASF SE (DE) | 2013-12-25 | — | — | EP | disclosed |
| US-8501748-B2 | Method for the production of β-ketonitriles | BASF SE (DE) | 2013-08-06 | — | — | US | disclosed |
| EP-2601166-A1 | COSMETIC PREPARATIONS | Cognis IP Management GmbH (DE) | 2013-06-12 | — | — | EP | disclosed |
| US-20130005970-A1 | Method for the production of beta-ketonitriles | BASF SE (DE) | 2013-01-03 | — | — | US | disclosed |
| US-8309751-B2 | Method for the production of β-ketonitriles | BASF SE (DE) | 2012-11-13 | — | — | US | disclosed |
| US-20120197025-A1 | ORGANOPHOSPHORUS COMPOUNDS BASED ON TETRAPHENOL (TP)-SUBSTITUTED STRUCTURES | EVONIK OXENO GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| EP-2426101-A1 | Cosmetic preparations | Cognis IP Management GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| EP-2426101-A1 | Cosmetic preparations | Cognis IP Management GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2012016642-A1 | COSMETIC PREPARATIONS | COGNIS IP MANAGEMENT GMBH (DE) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012016642-A1 | COSMETIC PREPARATIONS | COGNIS IP MANAGEMENT GMBH (DE) | 2012-02-09 | — | — | WO | disclosed |
| US-20100105903-A1 | Method for the production of beta-ketonitriles | BASF SE (DE) | 2010-04-29 | — | — | US | disclosed |
| EP-2132167-A1 | METHOD FOR THE PRODUCTION OF -KETONITRILES | BASF SE (DE) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008107397-A1 | METHOD FOR THE PRODUCTION OF β-KETONITRILES | BASF SE (DE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005970-A1 | Method for the production of beta-ketonitriles | AKR1C3, AKR1C4, AKR1C1 | LMNA 262/4885CYP3A4 126/4885OPRM1 3316/4885 |
| US-20100105903-A1 | Method for the production of beta-ketonitriles | AKR1C3, AKR1C4, AKR1C1 | LMNA 262/4885CYP3A4 126/4885OPRM1 3316/4885 |
| US-20120197025-A1 | ORGANOPHOSPHORUS COMPOUNDS BASED ON TETRAPHENOL (TP)-SUBSTITUTED STRUCTURES | PTMS, HPD, INPPL1 | LMNA 2512/4885CYP3A4 532/4885OPRM1 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.